LCA
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (NCT03920007) | Atsena Therapeutics Inc. | 2019-10-22 |
Track LCA automatically
Every clearance here is in the API, with alerts when new ones post.